Hyperleukocytotic secondary acute myeloid leukemia (AML) with sole monosomy 7 as sequela of Philadelphia-chromosome positive chronic myeloid leukemia (CML)
First published: 10 November 2009
Michael Lübbert, MD, PhD, Department of Internal Medicine, Division of Hematology and Oncology, Albert-Ludwigs-University, Freiburg, Hugstetter Str. 55, 79106 Freiburg, Germany.Tel: (49) 761 270 3279; Fax: (49) 761 270 3697; e-mail:
[email protected] No abstract is available for this article.
References
- 1
Jabbour E,
Kantarjian H,
Abruzzo LV,
et al.
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Blood
2007; 110: 2991–5.
- 2
Bumm T,
Müller C,
Al-Ali HK,
et al.
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib cut restoration of polyclonal hematopoiesis in the majority.
Blood
2003; 101: 1941–9.
- 3
Terre C,
Eclache V,
Rousselot P,
et al.
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.
Leukemia
2004; 18: 1340–6.
- 4
Lübbert M,
Rüter B,
Claus R,
et al.
Continued low-dose decitabine (DAC) is an active first-line treatment in all cytogenetic subgroups of older AML patients: results of the FR00331 multicenter phase II study [abstract].
Blood
2007; 110: 300.
- 5
Raj K,
John A,
Ho A,
et al.
CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine.
Leukemia
2007; 21: 1937–44.
- 6
Rüter B,
Wijermans P,
Claus R,
Kunzmann R,
Lübbert M.
Preferential cytogenetic response to continuous intravenous low-dose decitabine (DAC) administration in myelodysplastic syndrome with monosomy 7.
Blood
2007; 110: 1080–2.
- 7
Kovitz C,
Kantarjian H,
Garcia-Manero G,
Abruzzo LV,
Cortes J.
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
Blood
2006; 108: 2811–3.
- 8
Perel JM,
McCarthy C,
Walker O,
Irving I,
Williams B,
Kennedy GA.
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Haematologica
2005; 90 (Suppl.):ECR25.
